Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta
JAMA · 14.07.2026 · 336 (2) · 116
DOI: 10.1001/jama.2026.6889 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 14.07.2026. Verfasst von Jannie Dahl Hald und 43 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Fractures, Bone, Osteogenesis Imperfecta, Teriparatide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Osteogenesis imperfecta causes multiple fractures throughout life, causing substantial morbidity.
Objective
To determine whether the parathyroid hormone analogue teriparatide followed by zoledronic acid reduces the risk of fractures in adults with osteogenesis imperfecta. Design, Setting, and Participants Multicenter open-label, parallel-group, randomized clinical trial, conducted between May 17, 2017, and March 21, 2025, in adults attending one of 27 referral centers with a clinical diagnosis of osteogenesis imperfecta. Bone mineral density (BMD) was measured by dual x-ray absorptiometry and bone turnover by serum procollagen type 1 N-terminal propeptide and C-terminal telopeptide of type 1 collagen. Fractures were confirmed by skeletal imaging. Several measures of health–related quality of life were assessed.
Interventions
Those in the active group received 20 μg of teriparatide daily by subcutaneous injection for 2 years followed by an infusion of 5 mg of zoledronic acid. In the standard care group, bisphosphonates and other bone-targeted medicines could be used but teriparatide and other bone anabolic drugs were prohibited. Main outcomes and measures The primary end point was the number of participants with imaging-proven incident fractures adjudicated by reviewers blinded to treatment allocation. Secondary end points included the total number of fractures, changes in BMD, biochemical markers of bone turnover, and health–related quality of life.
Results
Of the 350 individuals randomized, 176 were allocated to receive teriparatide plus zoledronic acid, 174 to standard care, and 1 withdrew, leaving 349 evaluable participants. The mean age was 43.7 years (188 females [53.9%]). Most had type I osteogenesis imperfecta caused by pathogenic variants in the type 1 collagen genes. In the teriparatide plus zoledronic acid group 65 of 176 (36.9%) had incident fractures compared with 63 of 173 (36.4%) in the standard care group (absolute risk reduction, –1.57%; 95% CI, –9.90% to 5.89%; hazard ratio, 0.97; 95% CI, 0.68 to 1.38). Lumbar spine and total hip BMD increased significantly more with teriparatide plus zoledronic acid than standard care. Several quality-of-life measures favored teriparatide plus zoledronic acid. Adverse events were similar in both groups. Conclusions and Relevance This randomized clinical trial among adults with osteogenesis imperfecta found that teriparatide plus zoledronic acid did not reduce fracture risk compared with standard care despite significantly increasing BMD, suggesting the importance of reduced bone quality rather than low bone density in the pathogenesis of fracture. Trial Registration isrctn.org Identifier: ISRCTN15313991
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Endocrinology, Aarhus University Hospital, Aarhus, Denmark.
- Centre for Rare Disorders, Aarhus University Hospital, Aarhus, Denmark.
- Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
- Metabolic Bone Clinic, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom.
- Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom.
- Cambridge University Hospitals NHS Trust, Addenbrookes Hospital, Cambridge, United Kingdom.
Zitieren
APA
Hald, J. D., Weir, C. J., Keerie, C., Dewar, L., MacLean, M., Milne, L., Keen, R., Walsh, J. S., Poole, K. E. S., Langdahl, B. L., Lindsay, J. R., Ghouri, N., Hollick, R., Aspray, T., Crowley, R. K., Cohen-Solal, M., Hassan-Smith, Z., Tuck, S., Curtis, E. M., …, & TOPaZ Investigators (2026). Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta. JAMA, 336(2), 116. https://doi.org/10.1001/jama.2026.6889
Vancouver
Hald JD, Weir CJ, Keerie C, Dewar L, MacLean M, Milne L, et al. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta. JAMA. 2026;336(2):116. doi:10.1001/jama.2026.6889
BibTeX
@article{Hald2026,
author = {Hald, Jannie Dahl and Weir, Christopher J and Keerie, Catriona and Dewar, Lorna and MacLean, Morag and Milne, Lynsey and Keen, Richard and Walsh, Jennifer S and Poole, Kenneth E S and Langdahl, Bente L and Lindsay, John R and Ghouri, Nazim and Hollick, Rosemary and Aspray, Terry and Crowley, Rachel K and Cohen-Solal, Martine and Hassan-Smith, Zaki and Tuck, Stephen and Curtis, Elizabeth M and Harvey, Nicholas C and Eekhoff, Elisabeth Marelise W and Feenstra, Johannes and Hampson, Geeta and Stone, Mike and Turton, Jane and Patel, Prashanth and Siddiqi, Mashood and Munro, Robin and Roy, Matthew and Paskins, Zoe and Narayanan, Deepa and Malcolm, Ellen and Javaid, Muhammad Kassim and Osborne, Patricia and Tang, Jonathan C Y and Lam, Wayne and Moore, David and Black, Holly A and Duckworth, Andrew D and Makaram, Navni S and Guo, Tianyu and Stenhouse, Gregor and Ralston, Stuart H and TOPaZ Investigators, TOPaZ Investigators},
title = {Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta},
journal = {JAMA},
year = {2026},
volume = {336},
number = {2},
pages = {116},
doi = {10.1001/jama.2026.6889}
}
EUVIMED